Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
United States
Univ Cali Irvine ALS Neuromuscular, Orange, California Wake Forest Univ School of Medicine, Winston-Salem, North Carolina Houston Methodist Hospital, Houston, Texas France
Novartis Investigative Site, Bordeaux Novartis Investigative Site, Brest